-
1دورية أكاديمية
المؤلفون: Nylen, C, Mechera, R, Marechal-Ross, I, Tsang, V, Chou, A, Gill, AJ, Clifton-Bligh, RJ, Robinson, BG, Sywak, MS, Sidhu, SB, Glover, AR
المصدر: Cancers. 12(8)
مصطلحات موضوعية: Medicin och hälsovetenskap
-
2دورية أكاديمية
المؤلفون: Mauro, D, Manou-Stathopoulou, S, Rivellese, F, Sciacca, E, Goldmann, K, Tsang, V, Lucey-Clayton, I, Pagani, S, Alam, F, Pyne, D, Rajakariar, R, Gordon, PA, Whiteford, J, Bombardieri, M, Pitzalis, C, Lewis, MJ
مصطلحات موضوعية: Ubiquitination, TLR7, Systemic lupus erythematosus, B-cells, Autoimmunity
العلاقة: JOURNAL OF AUTOIMMUNITY; ARTN 103023; https://qmro.qmul.ac.uk/xmlui/handle/123456789/85700Test
الإتاحة: https://doi.org/10.1016/j.jaut.2023.103023Test
https://qmro.qmul.ac.uk/xmlui/handle/123456789/85700Test -
3دورية أكاديمية
المؤلفون: Zhou, Z, Jardine, MJ, Li, Q, Neuen, BL, Cannon, CP, De Zeeuw, D, Edwards, R, Levin, A, Mahaffey, KW, Perkovic, V, Neal, B, Lindley, RI, Guerrero, RAA, Aizenberg, D, Albisu, JP, Alvarisqueta, A, Bartolacci, I, Berli, MA, Bordonava, A, Calella, P, Cantero, MC, Cartasegna, LR, Cercos, E, Coloma, GC, Colombo, H, Commendatore, V, Cuadrado, J, Cuneo, CA, Cusumano, AM, Douthat, WG, Dran, RD, Farias, E, Fernandez, MF, Finkelstein, H, Fragale, G, Fretes, JO, Garcia, NH, Gastaldi, A, Gelersztein, E, Glenny, JA, Gonzalez, JP, Del Carmen Gonzalez Colaso, P, Goycoa, C, Greloni, GC, Guinsburg, A, Hermida, S, Juncos, LI, Klyver, MI, Kraft, F, Krynski, F, Lanchiotti, PV, De La Fuente, RAL, Marchetta, N, Mele, P, Nicolai, S, Novoa, PA, Orio, SI, Otreras, F, Oviedo, A, Raffaele, P, Resk, JH, Rista, L, Papini, NR, Sala, J, Santos, JC, Schiavi, LB, Sessa, H, Casabella, TS, Ulla, MR, Valdez, M, Vallejos, A, Villarino, A, Visco, VE, Wassermann, A, Zaidman, CJ, Cheung, NW, Droste, C, Fraser, I, Johnson, D, Mah, PM, Nicholls, K, Packham, D, Proietto, J, Roberts, A, Roger, S, Tsang, V, Raduan, RA, Da Costa, FAA, Amodeo, C, Turatti, LAA, Bregman, R, Sanches, FCC, Canani, LH, Chacra, AR, Borges, JLC, Vêncio, SAC, Da Silva Franco, RJ, D'Avila, D, De Souza Portes, E, De Souza, P, Phillips, Andrea
المصدر: urn:ISSN:0039-2499 ; urn:ISSN:1524-4628 ; Stroke, 52, 5, 1545-1556
مصطلحات موضوعية: Clinical Research, Stroke, Kidney Disease, Clinical Trials and Supportive Activities, Diabetes, Renal and urogenital, 3 Good Health and Well Being, Atrial Fibrillation, Canagliflozin, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Humans, Meta-Analysis as Topic, Sodium-Glucose Transporter 2 Inhibitors, glomerular filtration rate, hemorrhagic stroke, ischemic stroke, CREDENCE Trial Investigators, anzsrc-for: 1102 Cardiorespiratory Medicine and Haematology, anzsrc-for: 1103 Clinical Sciences, anzsrc-for: 1109 Neurosciences
الوصف: BACKGROUND AND PURPOSE: Chronic kidney disease with reduced estimated glomerular filtration rate or elevated albuminuria increases risk for ischemic and hemorrhagic stroke. This study assessed the effects of sodium glucose cotransporter 2 inhibitors (SGLT2i) on stroke and atrial fibrillation/flutter (AF/AFL) from CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation) and a meta-Analysis of large cardiovascular outcome trials (CVOTs) of SGLT2i in type 2 diabetes mellitus. METHODS: CREDENCE randomized 4401 participants with type 2 diabetes mellitus and chronic kidney disease to canagliflozin or placebo. Post hoc, we estimated effects on fatal or nonfatal stroke, stroke subtypes, and intermediate markers of stroke risk including AF/AFL. Stroke and AF/AFL data from 3 other completed large CVOTs and CREDENCE were pooled using random-effects meta-Analysis. RESULTS: In CREDENCE, 142 participants experienced a stroke during follow-up (10.9/1000 patient-years with canagliflozin, 14.2/1000 patient-years with placebo; hazard ratio [HR], 0.77 [95% CI, 0.55-1.08]). Effects by stroke subtypes were: ischemic (HR, 0.88 [95% CI, 0.61-1.28]; n=111), hemorrhagic (HR, 0.50 [95% CI, 0.19-1.32]; n=18), and undetermined (HR, 0.54 [95% CI, 0.20-1.46]; n=17). There was no clear effect on AF/AFL (HR, 0.76 [95% CI, 0.53-1.10]; n=115). The overall effects in the 4 CVOTs combined were: Total stroke (HRpooled, 0.96 [95% CI, 0.82-1.12]), ischemic stroke (HRpooled, 1.01 [95% CI, 0.89-1.14]), hemorrhagic stroke (HRpooled, 0.50 [95% CI, 0.30-0.83]), undetermined stroke (HRpooled, 0.86 [95% CI, 0.49-1.51]), and AF/AFL (HRpooled, 0.81 [95% CI, 0.71-0.93]). There was evidence that SGLT2i effects on total stroke varied by baseline estimated glomerular filtration rate (P=0.01), with protection in the lowest estimated glomerular filtration rate (45 mL/min/1.73 m2]) subgroup (HRpooled, 0.50 [95% CI, 0.31-0.79]). CONCLUSIONS: Although we found no clear effect of SGLT2i on total stroke in CREDENCE or across ...
وصف الملف: application/pdf
العلاقة: http://hdl.handle.net/1959.4/unsworks_76562Test; https://unsworks.unsw.edu.au/bitstreams/8669c703-7b49-4eb9-8c95-db1fb6f5816f/downloadTest; https://doi.org/10.1161/STROKEAHA.120.031623Test
الإتاحة: https://doi.org/10.1161/STROKEAHA.120.031623Test
http://hdl.handle.net/1959.4/unsworks_76562Test
https://unsworks.unsw.edu.au/bitstreams/8669c703-7b49-4eb9-8c95-db1fb6f5816f/downloadTest -
4دورية أكاديمية
المؤلفون: Hadjicosta, E, Franklin, R, Seale, A, Stumper, O, Tsang, V, Anderson, DR, Pagel, C, Crowe, S, Espuny Pujol, F, Ridout, D, Brown, KL
المصدر: Heart (2021) (In press).
مصطلحات موضوعية: congenital, health care, heart defects, outcome assessment
الوصف: Objective: Given the paucity of long-term outcome data for complex congenital heart disease (CHD), we aimed to describe the treatment pathways and survival for patients who started interventions for functionally univentricular heart (FUH) conditions, excluding hypoplastic left heart syndrome. // Methods: We performed a retrospective cohort study using all procedure records from the National Congenital Heart Diseases Audit for children born in 2000–2018. The primary outcome was mortality, ascertained from the Office for National Statistics in 2020. // Results: Of 53 615 patients, 1557 had FUH: 55.9% were boys and 67.4% were of White ethnic groups. The largest diagnostic categories were tricuspid atresia (28.9%), double inlet left ventricle (21.0%) and unbalanced atrioventricular septal defect (AVSD) (15.2%). The ages at staged surgery were: initial palliation 11.5 (IQR 5.5–43.5) days, cavopulmonary shunt 9.2 (IQR 6.0–17.1) months and Fontan 56.2 (IQR 45.5–70.3) months. The median follow-up time was 10.8 (IQR 7.0–14.9) years and the 1, 5 and 10-year survival rates after initial palliation were 83.6% (95% CI 81.7% to 85.4%), 79.4% (95% CI 77.3% to 81.4%) and 77.2% (95% CI 75.0% to 79.2%), respectively. Higher hazards were present for unbalanced AVSD HR 2.75 (95% CI 1.82 to 4.17), atrial isomerism HR 1.75 (95% CI 1.14 to 2.70) and low weight HR 1.65 (95% CI 1.13 to 2.41), critical illness HR 2.30 (95% CI 1.67 to 3.18) or acquired comorbidities HR 2.71 (95% CI 1.82 to 4.04) at initial palliation. // Conclusion: Although treatment pathways for FUH are complex and variable, nearly 8 out of 10 children survived to 10 years. Longer-term analyses of outcome based on diagnosis (rather than procedure) can inform parents, patients and clinicians, driving practice improvements for complex CHD.
وصف الملف: text
العلاقة: https://discovery.ucl.ac.uk/id/eprint/10137362/1/Pagel_heartjnl-2021-319677.full.pdfTest; https://discovery.ucl.ac.uk/id/eprint/10137362Test/
-
5دورية أكاديمية
المؤلفون: Annio, G, Torii, R, Ducci, A, Muthurangu, V, Tsang, V, Burriesci, G
المصدر: Annals of Biomedical Engineering , 49 pp. 3481-3493. (2021)
مصطلحات موضوعية: 4D Flow CMR, CFD, Cardiovascular flow, PIV, U-bend
الوصف: Flow-sensitive four-dimensional Cardiovascular Magnetic Resonance Imaging (4D Flow CMR) has increasingly been utilised to characterise patients' blood flow, in association with patiens' state of health and disease, even though spatial and temporal resolutions still constitute a limit. Computational fluid dynamics (CFD) is a powerful tool that could expand these information and, if integrated with experimentally-obtained velocity fields, would enable to derive a large variety of the flow descriptors of interest. However, the accuracy of the flow parameters is highly influenced by the quality of the input data such as the anatomical model and boundary conditions typically derived from medical images including 4D Flow CMR. We previously proposed a novel approach in which 4D Flow CMR and CFD velocity fields are integrated to obtain an Enhanced 4D Flow CMR (EMRI), allowing to overcome the spatial-resolution limitation of 4D Flow CMR, and enable an accurate quantification of flow. In this paper, the proposed approach is validated in a U bend channel, an idealised model of the human aortic arch. The flow patterns were studied with 4D Flow CMR, CFD and EMRI, and compared with high resolution 2D PIV experiments obtained in pulsatile conditions. The main strengths and limitations of 4D Flow CMR and CFD were illustrated by exploiting the accuracy of PIV by comparing against PIV velocity fields. EMRI flow patterns showed a better qualitative and quantitative agreement with PIV results than the other techniques. EMRI enables to overcome the experimental limitations of MRI-based velocity measurements and the modelling simplifications of CFD, allowing an accurate prediction of complex flow patterns observed experimentally, while satisfying mass and momentum balance equations.
وصف الملف: text
العلاقة: https://discovery.ucl.ac.uk/id/eprint/10131247/1/Manuscript%20EMRI.pdfTest; https://discovery.ucl.ac.uk/id/eprint/10131247Test/
-
6دورية أكاديمية
المؤلفون: Issitt, R, Booth, J, Crook, R, Robertson, A, Molyneux, V, Richardson, R, Cross, N, Shaw, M, Tsang, V, Muthurangu, V, Sebire, NJ, Burch, M, Fenton, M
المصدر: The Journal of Heart and Lung Transplantation (2021) (In press).
مصطلحات موضوعية: cardiopulmonary bypass, heart transplantation, immunoadsorption, pediatrics
الوصف: BACKGROUND: Intraoperative anti-A/B immunoadsorption (ABO-IA) was recently introduced for ABO-incompatible heart transplantation. Here we report the first case series of patients transplanted with ABO-IA, and compare outcomes with those undergoing plasma exchange facilitated ABO-incompatible heart transplantation (ABO-PE). METHODS: Data were retrospectively analysed on all ABO-incompatible heart transplants undertaken at a single centre between January 1, 2000 and June 1, 2020. Data included all routine laboratory tests, demographics and pre-operative characteristics, intraoperative details and post-operative outcomes. Primary outcome measures were volume of blood product transfusions, maximum post-transplant isohaemagglutinin titres, occurrence of rejection and graft survival. Secondary outcome measures were length of intensive care and hospital stay. Demographic and survival data were also obtained for ABO-compatible transplants during the same time period for comparison. RESULTS: Thirty-seven patients underwent ABO-incompatible heart transplantation, with 27 (73%) using ABO-PE and 10 (27%) using ABO-IA. ABO-IA patients were significantly older than ABO-PE patients (p < 0.001) and the total volume of blood products transfused during the hospital admission was significantly lower (164 [126-212] ml/kg vs 323 [268-379] ml/kg, p < 0.001). No significant differences were noted between methods in either pre or post-transplant maximum isohaemagglutinin titres, incidence of rejection, length of intensive care or total hospital stay. Survival comparison showed no significant difference between antibody reduction methods, or indeed ABO-compatible transplants (p = 0.6). CONCLUSIONS: This novel technique appears to allow a significantly older population than typical to undergo ABO-incompatible heart transplantation, as well as significantly reducing blood product utilization. Furthermore, intraoperative anti-A/B immunoadsorption does not demonstrate increased early post-transplant isohaemagglutinin accumulation or ...
وصف الملف: text
العلاقة: https://discovery.ucl.ac.uk/id/eprint/10130842/1/1-s2.0-S1053249821023251-main.pdfTest; https://discovery.ucl.ac.uk/id/eprint/10130842Test/
-
7دورية أكاديمية
المؤلفون: Boethig D., Horke A., Hazekamp M., Meyns B., Rega F., Van Puyvelde J., Hubler M., Schmiady M., Ciubotaru A., Stellin G., Padalino M., Tsang V., Jashari R., Bobylev D., Tudorache I., Cebotari S., Haverich A., Sarikouch S.
المساهمون: Boethig, D., Horke, A., Hazekamp, M., Meyns, B., Rega, F., Van Puyvelde, J., Hubler, M., Schmiady, M., Ciubotaru, A., Stellin, G., Padalino, M., Tsang, V., Jashari, R., Bobylev, D., Tudorache, I., Cebotari, S., Haverich, A., Sarikouch, S.
مصطلحات موضوعية: Allograft, Decellularization, Heart valve disease, Tissue engineering
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/30879050; info:eu-repo/semantics/altIdentifier/wos/WOS:000493091000012; volume:56; issue:3; firstpage:503; lastpage:509; numberofpages:7; journal:EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY; http://hdl.handle.net/11577/3314767Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85071700284
-
8دورية أكاديمية
المؤلفون: Mahaffey, KW, Jardine, MJ, Bompoint, S, Cannon, CP, Neal, B, Heerspink, HJL, Charytan, DM, Edwards, R, Agarwal, R, Bakris, G, Bull, S, Capuano, G, de Zeeuw, D, Greene, T, Levin, A, Pollock, C, Sun, T, Wheeler, DC, Yavin, Y, Zhang, H, Zinman, B, Rosenthal, N, Brenner, BM, Perkovic, V, Guerrero, RAA, Aizenberg, D, Albisu, JP, Alvarisqueta, A, Bartolacci, I, Berli, MA, Bordonava, A, Calella, P, Cantero, MC, Cartasegna, LR, Cercos, E, Coloma, GC, Colombo, H, Commendatore, V, Cuadrado, J, Cuneo, CA, Cusumano, AM, Douthat, WG, Dran, RD, Farias, E, Fernandez, MF, Finkelstein, H, Fragale, G, Fretes, JO, Garcia, NH, Gastaldi, A, Gelersztein, E, Glenny, JA, Gonzalez, JP, Colaso, PDG, Goycoa, C, Greloni, GC, Guinsburg, A, Hermida, S, Juncos, LI, Klyver, MI, Kraft, F, Krynski, F, Lanchiotti, PV, de la Fuente, RAL, Marchetta, N, Mele, P, Nicolai, S., Novoa, PA, Orio, SI, Otreras, F, Oviedo, A, Raffaele, P, Resk, JH, Rista, L, Papini, NR, Sala, J, Santos, JC, Schiavi, LB, Sessa, H, Casabella, TS, Ulla, MR, Valdez, M, Vallejos, A, Villarino, A, Visco, VE, Wassermann, A, Zaidman, CJ, Cheung, NW, Droste, C, Fraser, I, Johnson, D, Mah, PM, Nicholls, K, Packham, D, Proietto, J, Roberts, A, Roger, S, Tsang, V, Raduan, RA, da Costa, FAA, Amodeo, C, Turatti, LAA, Bregman, R, Sanches, FCC, Canani, LH, Chacra, AR, Cunha Borges, JL, Vencio, SAC, Franco, RJD, D'Avila, D, Portes, ED, de Souza, P, Deboni, LM, Fraige, F, Neto, BG, Gomes, M, Kohara, SK, Keitel, E, Saraiva, JFK, Lisboa, HRK, Contieri, FLD, Milagres, R, Montenegro, R, de Brito, CM, Hissa, MN, Sabbag, ARN, Noronha, I, Panarotto, D, Pecoits, R, Pereira, MA, Saporito, W, Scotton, AS, Schuch, T, de Almeida, RS, Ramos, CS, Felicio, JS, Thome, F, Hachmann, JCT, Yamada, S, Hayashida, CY, Petry, TBZ, Zanella, MT, Andreeva, V, Angelova, A, Dimitrov, S, Genadieva, V, Genova-Hristova, G, Hristozov, K, Kamenov, Z, Koundurdjiev, A, Lozanov, L, Margaritov, V, Nonchev, B, Rangelov, R, Shinkov, A., Temelkova, M, Velichkova, E, Yakov, A, Aggarwal, N, Aronson, R, Bajaj, H, Cherney, D, Chouinard, G, Conway, J, Cournoyer, S, DaRoza, G, De Serres, S, Dube, F, Goldenberg, R, Gupta, A, Gupta, M, Henein, S, Khandwala, H, Leiter, L, Madore, F, McMahon, A, Muirhead, N, Pichette, V, Rabasa-Lhoret, R, Steele, A, Tangri, N, Torshizi, A, Woo, V, Zalunardo, Nadia, Fernandez Montenegro, Maria Alicia, Godoy Jorquera, Juan Gonzalo, Medina Farina, Marcelo, Saavedra Gajardo, Victor, Vejar, Margarita, Chen, Nan, Chen, Qinkai, Gan, Shenglian, Kong, Yaozhong, Li, Detian, Li, Wenge, Li, Xuemei, Lin, Hongli, Liu, Jian, Lu, Weiping, Mao, Hong, Ren, Yan, Song, Weihong, Sun, Jiao, Sun, Lin, Tu, Ping, Wang, Guixia, Yang, Jinkui, Yin, Aiping, Yu, Xueqing, Zhao, Minghui, Zheng, Hongguang, Accini Mendoza, Jose Luis, Arcos, Edgar, Avendano, Jorge, Diaz Ruiz, Jorge Ernesto Andres, Garcia Ortiz, Luis Hernando, Gonzalez, Alexander, Hernandez Triana, Eric, Diego Higuera, Juan, Malaver, Natalia, Ines Molina de Salazar, Dora, Rosero, Ricardo, Terront Lozano, Monica Alexandra, Valderrama Cometa, Luis, Valenzuela, Alex, Vargas Alonso, Ruben Dario, Villegas, Ivan, Yupanqui, Hernan, Bartaskova, Dagmar, Barton, Petr, Belobradkova, Jana, Dohnalova, Lenka, Drasnar, Tomas, Ferkl, Richard, Halciakova, Katarina, Klokocnikova, Vera, Kovar, Richard, Lastuvka, Jiri, Lukac, Martin, Pesickova, Satu, Peterka, Karel, Pumprla, Jiri, Rychlik, Ivan, Saudek, Frantisek, Tesar, Vladimir, Valis, Martin, Weiner, Pavel, Zemek, Stanislav, Alamartine, Eric, Borot, Sophie, Cariou, Bertrand, Dussol, Bertrand, Fauvel, Jean-Pierre, Gourdy, Pierre, Klein, Alexandre, Le Meur, Yannick, Penfornis, Alfred, Roussel, Ronan, Saulnier, Pierre-Jean, Thervet, Eric, Zaoui, Philippe, Burst, Volker, Faghih, Markus, Faulmann, Grit, Haller, Hermann, Jerwan-Keim, Reinhold, Maxeiner, Stephan, Paschen, Bjoern, Plassmann, Georg, Rose, Ludger, Gonzalez Orellana, Ronaldo Arturo, Paul Haase, Franklin, Moreira Diaz, Juan Pablo, Ramirez Roca, Luis Alberto, Sanchez Arenales, Jose Antonio, Sanchez Polo, Jose Vicente, Turcios Juarez, Erick, Csecsei, Gyongyi, Csiky, Botond, Danos, Peter, Deak, Laszlo, Dudas, Mihaly, Harcsa, Eleonora, Keltai, Katalin, Keresztesi, Sandor, Kiss, Konyves, Laszlo, Major, Lajos, Mileder, Margit, Molnar, Marta, Mucsi, Janos, Oroszlan, Tamas, Ory, Ivan, Paragh, Gyorgy, Peterfai, Eva, Petro, Gizella, Revesz, Katalin, Takacs, Robert, Vangel, Sandor, Vasas, Szilard, Zsom, Marianna, Abraham, Oomman, Bhushan, Raju Sree, Deepak, Dewan, Edwin, Fernando M., Gopalakrishnan, Natarajan, Gracious, Noble, Hansraj, Alva, Jain, Dinesh, Keshavamurthy, C. B., Khullar, Dinesh, Manisha, Sahay, Peringat, Jayameena, Prasad, Narayan, Satyanarayana, Rao K., Sreedhar, Reddy, Sreelatha, Melemadathil, Sudhakar, Bhimavarapu, Vyasam, Ramesh Chandra, Bonadonna, Riccardo, Castellino, Pietro, Ceriello, Antonio, Chiovato, Luca, De Cosmo, Salvatore, De Nicola, Luca, Derosa, Giuseppe, Di Carlo, Alberto, Di Cianni, Graziano, Frasca, Giovanni, Fuiano, Giorgio, Gambaro, Giovanni, Garibotto, Giacomo, Giorda, Carlo, Malberti, Fabio, Mandreoli, Marcora, Mannucci, Edoardo, Orsi, Emanuela, Piatti, Piermarco, Santoro, Domenico, Sasso, Ferdinando Carlo, Serviddio, Gaetano, Stella, Andrea, Trevisan, Roberto, Veronelli, Anna Maria, Zanoli, Luca, Akiyama, Hitoshi, Aoki, Hiromi, Asano, Akimichi, Iitsuka, Tadashi, Kajiyama, Shizuo, Kashine, Susumu, Kawada, Toshio, Kodera, Takamoto, Kono, Hiroshi, Koyama, Kazunori, Kumeda, Yasuro, Miyauchi, Shozo, Mizuyama, Kazuyuki, Niiya, Tetsuji, Oishi, Hiroko, Ota, Satoshi, Sakakibara, Terue, Takai, Masahiko, Tomonaga, Osamu, Tsujimoto, Mitsuru, Wada, Takashi, Wakasugi, Masakiyo, Wakida, Yasushi, Watanabe, Takayuki, Yamada, Masayo, Yanagida, Kazuhiro, Yanase, Toshihiko, Yumita, Wataru
المساهمون: Mahaffey, Kw, Jardine, Mj, Bompoint, S, Cannon, Cp, Neal, B, Heerspink, Hjl, Charytan, Dm, Edwards, R, Agarwal, R, Bakris, G, Bull, S, Capuano, G, de Zeeuw, D, Greene, T, Levin, A, Pollock, C, Sun, T, Wheeler, Dc, Yavin, Y, Zhang, H, Zinman, B, Rosenthal, N, Brenner, Bm, Perkovic, V, Guerrero, Raa, Aizenberg, D, Albisu, Jp, Alvarisqueta, A, Bartolacci, I, Berli, Ma, Bordonava, A, Calella, P, Cantero, Mc, Cartasegna, Lr, Cercos, E, Coloma, Gc, Colombo, H, Commendatore, V, Cuadrado, J, Cuneo, Ca, Cusumano, Am, Douthat, Wg, Dran, Rd, Farias, E, Fernandez, Mf, Finkelstein, H, Fragale, G, Fretes, Jo, Garcia, Nh, Gastaldi, A, Gelersztein, E, Glenny, Ja, Gonzalez, Jp, Colaso, Pdg, Goycoa, C, Greloni, Gc, Guinsburg, A, Hermida, S, Juncos, Li, Klyver, Mi, Kraft, F, Krynski, F, Lanchiotti, Pv, de la Fuente, Ral, Marchetta, N, Mele, P, Nicolai, S., Novoa, Pa, Orio, Si, Otreras, F, Oviedo, A, Raffaele, P, Resk, Jh, Rista, L, Papini, Nr, Sala, J, Santos, Jc, Schiavi, Lb, Sessa, H, Casabella, T, Ulla, Mr, Valdez, M, Vallejos, A, Villarino, A, Visco, Ve, Wassermann, A, Zaidman, Cj, Cheung, Nw, Droste, C, Fraser, I, Johnson, D, Mah, Pm, Nicholls, K, Packham, D, Proietto, J, Roberts, A, Roger, S, Tsang, V, Raduan, Ra, da Costa, Faa
مصطلحات موضوعية: canagliflozin, clinical trial, diabetes mellitus, primary prevention, renal insufficiency, chronic, secondary prevention
الوصف: Background: Canagliflozin reduces the risk of kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, but effects on specific cardiovascular outcomes are uncertain, as are effects in people without previous cardiovascular disease (primary prevention). Methods: In CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation), 4401 participants with type 2 diabetes mellitus and chronic kidney disease were randomly assigned to canagliflozin or placebo on a background of optimized standard of care. Results: Primary prevention participants (n=2181, 49.6%) were younger (61 versus 65 years), were more often female (37% versus 31%), and had shorter duration of diabetes mellitus (15 years versus 16 years) compared with secondary prevention participants (n=2220, 50.4%). Canagliflozin reduced the risk of major cardiovascular events overall (hazard ratio [HR], 0.80 [95% CI, 0.67-0.95]; P=0.01), with consistent reductions in both the primary (HR, 0.68 [95% CI, 0.49-0.94]) and secondary (HR, 0.85 [95% CI, 0.69-1.06]) prevention groups (P for interaction=0.25). Effects were also similar for the components of the composite including cardiovascular death (HR, 0.78 [95% CI, 0.61-1.00]), nonfatal myocardial infarction (HR, 0.81 [95% CI, 0.59-1.10]), and nonfatal stroke (HR, 0.80 [95% CI, 0.56-1.15]). The risk of the primary composite renal outcome and the composite of cardiovascular death or hospitalization for heart failure were also consistently reduced in both the primary and secondary prevention groups (P for interaction >0.5 for each outcome). Conclusions: Canagliflozin significantly reduced major cardiovascular events and kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, including in participants who did not have previous cardiovascular disease.
وصف الملف: ELETTRONICO
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/31291786; info:eu-repo/semantics/altIdentifier/wos/WOS:000483552900013; volume:140 (9); firstpage:739; lastpage:750; numberofpages:12; journal:CIRCULATION; http://hdl.handle.net/11567/974809Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85071325197
الإتاحة: https://doi.org/10.1161/CIRCULATIONAHA.119.042007Test
http://hdl.handle.net/11567/974809Test -
9دورية أكاديمية
المؤلفون: Wray, J, Ridout, D, Jones, A, Davis, P, Wellman, P, Rodrigues, W, Hudson, E, Tsang, V, Pagel, C, Brown, KL
المصدر: The Annals of Thoracic Surgery , 112 (6) pp. 2055-2062. (2020)
الوصف: BACKGROUND: The majority of children now survive cardiac surgery, and the focus of quality improvement initiatives has shifted towards more complex outcome measures. Our aim was to study the impact of early post-operative morbidities on parent-reported patient quality of life and parental anxiety/depression over six months. METHODS: We undertook a prospective case matched cohort study in five UK children's cardiac centers, in which we compared measures of impact for patient categories of 'single morbidity', 'multiple morbidities' and 'extracorporeal life support (ECLS)' with 'no morbidity'. Measures were PedsQL and PHQ-4 at six weeks and six months post-surgery. We modelled the outcomes using mixed effects regression, adjusting for case mix and clustering within centers. RESULTS: We included 666 patients, operated at a median age of 81 days (IQR 10-325 days). At six weeks follow-up, significant adjusted differences to the reference group with no morbidity were found for total PedsQL scores, which were lower in ECLS (p=0.01), multiple morbidities (p<0.001) and single morbidity (p=0.04); and the proportion of parents with anxiety and depression, which were higher in multiple morbidities (p=0.04 and p=0.01 respectively). At six months, measures had improved in all morbidity groups: the only significant adjusted difference to the reference group was for physical PedsQL scores in ECLS (p=0.04) and multiple morbidities (p<0.01). CONCLUSIONS: Patient and parent wellbeing are strongly influenced by post-operative morbidities early after surgery, with improvement by six months. Family psychological support and holistic rehabilitation are vital for children who experience post-operative morbidities.
وصف الملف: text
العلاقة: https://discovery.ucl.ac.uk/id/eprint/10116882/3/Pagel_1-s2.0-S0003497520320300-main.pdfTest; https://discovery.ucl.ac.uk/id/eprint/10116882Test/
-
10دورية أكاديمية
المؤلفون: Hoskote, A, Ridout, D, Banks, V, Kakat, S, Lakhanpaul, M, Pagel, C, Franklin, RC, Witter, T, Lakhani, R, Tibby, SM, Anderson, D, Tsang, V, Wray, J, Brown, K
المصدر: Archives of Disease in Childhood (2020) (In press).
مصطلحات موضوعية: child development, congenital heart disease, early recognition tool, neurology, surveillance
الوصف: OBJECTIVE: To describe neurodevelopment and follow-up services in preschool children with heart disease (HD). DESIGN: Secondary analysis of a prospectively collected multicentre dataset. SETTING: Three London tertiary cardiac centres. PATIENTS: Preschool children<5 years of age: both inpatients and outpatients. METHODS: We analysed results of Mullen Scales of Early Learning (MSEL) and parental report of follow-up services in a representative convenience sample evaluated between January 2014 and July 2015 within a previous study. RESULTS: Of 971 preschool children: 577 (59.4%) had ≥1 heart operation, 236 (24.3%) had a known diagnosis linked to developmental delay (DD) ('known group') and 130 (13.4%) had history of clinical event linked to DD. On MSEL assessment, 643 (66.2%) had normal development, 181 (18.6%) had borderline scores and 147 (15.1%) had scores indicative of DD. Of 971 children, 609 (62.7%) were not receiving follow-up linked to child development and were more likely to be under these services with a known group diagnosis, history of clinical event linked to DD and DD (defined by MSEL). Of 236 in known group, parents of 77 (32.6%) and of 48 children not in a known group but with DD 29 (60.4%), reported no child development related follow-up. DD defined by MSEL assessment was more likely with a known group and older age at assessment. CONCLUSIONS: Our findings indicate that a 'structured neurodevelopmental follow-up pathway' in preschool children with HD should be considered for development and evaluation as children get older, with particular focus on those at higher risk.
وصف الملف: text
العلاقة: https://discovery.ucl.ac.uk/id/eprint/10110161/3/Pagel_Hoskote_Neurodevelopmental_status_and_follow-up_in_pre-school_children_with_heart_disease_in_London_UK_Archives_Revision_clean_12_March_2020.pdfTest; https://discovery.ucl.ac.uk/id/eprint/10110161Test/
النص الكامل